Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice

Glucagon like peptide-1 (GLP-1) receptor agonists such as exendin-4 have been widely used but their short half-life limits their therapeutic value. The recombinant protein, E2HSA, is a novel, long-acting GLP-1 receptor agonist generated by the fusion of exendin-4 with human serum albumin. In mouse p...

Full description

Saved in:
Bibliographic Details
Main Authors: Shaocong Hou, Caina Li, Yi Huan, Shuainan Liu, Quan Liu, Sujuan Sun, Qian Jiang, Chunming Jia, Zhufang Shen
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2015/817839
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849399033893748736
author Shaocong Hou
Caina Li
Yi Huan
Shuainan Liu
Quan Liu
Sujuan Sun
Qian Jiang
Chunming Jia
Zhufang Shen
author_facet Shaocong Hou
Caina Li
Yi Huan
Shuainan Liu
Quan Liu
Sujuan Sun
Qian Jiang
Chunming Jia
Zhufang Shen
author_sort Shaocong Hou
collection DOAJ
description Glucagon like peptide-1 (GLP-1) receptor agonists such as exendin-4 have been widely used but their short half-life limits their therapeutic value. The recombinant protein, E2HSA, is a novel, long-acting GLP-1 receptor agonist generated by the fusion of exendin-4 with human serum albumin. In mouse pancreatic NIT-1 cells, E2HSA activated GLP-1 receptor with similar efficacy as exendin-4. After single-dose administration in ICR mice, E2HSA showed prolonged glucose lowering effects which lasted up to four days and extended inhibition on gastric emptying for at least 72 hours. Chronic E2HSA treatment in db/db mice significantly improved glucose tolerance, reduced elevated nonfasting and fasting plasma glucose levels, and also decreased HbA1c levels. E2HSA also increased insulin secretion and decreased body weight and appetite. Furthermore, immunofluorescence analysis showed that E2HSA increased β-cell area, improved islet morphology, and reduced β-cell apoptosis. In accordance with the promotion of β-cell function and survival, E2HSA upregulated genes such as Irs2, Pdx-1, Nkx6.1, and MafA and downregulated the expression levels of FoxO1 and proapoptotic Bcl-2 family proteins. In conclusion, with prolonged glucose lowering effects and promoting β-cell function and survival, the fusion protein, E2HSA, is a promising new therapeutic for once weekly treatment of type 2 diabetes.
format Article
id doaj-art-9dbef69b82094db793cee8a663705007
institution Kabale University
issn 2314-6745
2314-6753
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Journal of Diabetes Research
spelling doaj-art-9dbef69b82094db793cee8a6637050072025-08-20T03:38:26ZengWileyJournal of Diabetes Research2314-67452314-67532015-01-01201510.1155/2015/817839817839Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db MiceShaocong Hou0Caina Li1Yi Huan2Shuainan Liu3Quan Liu4Sujuan Sun5Qian Jiang6Chunming Jia7Zhufang Shen8State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaGlucagon like peptide-1 (GLP-1) receptor agonists such as exendin-4 have been widely used but their short half-life limits their therapeutic value. The recombinant protein, E2HSA, is a novel, long-acting GLP-1 receptor agonist generated by the fusion of exendin-4 with human serum albumin. In mouse pancreatic NIT-1 cells, E2HSA activated GLP-1 receptor with similar efficacy as exendin-4. After single-dose administration in ICR mice, E2HSA showed prolonged glucose lowering effects which lasted up to four days and extended inhibition on gastric emptying for at least 72 hours. Chronic E2HSA treatment in db/db mice significantly improved glucose tolerance, reduced elevated nonfasting and fasting plasma glucose levels, and also decreased HbA1c levels. E2HSA also increased insulin secretion and decreased body weight and appetite. Furthermore, immunofluorescence analysis showed that E2HSA increased β-cell area, improved islet morphology, and reduced β-cell apoptosis. In accordance with the promotion of β-cell function and survival, E2HSA upregulated genes such as Irs2, Pdx-1, Nkx6.1, and MafA and downregulated the expression levels of FoxO1 and proapoptotic Bcl-2 family proteins. In conclusion, with prolonged glucose lowering effects and promoting β-cell function and survival, the fusion protein, E2HSA, is a promising new therapeutic for once weekly treatment of type 2 diabetes.http://dx.doi.org/10.1155/2015/817839
spellingShingle Shaocong Hou
Caina Li
Yi Huan
Shuainan Liu
Quan Liu
Sujuan Sun
Qian Jiang
Chunming Jia
Zhufang Shen
Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice
Journal of Diabetes Research
title Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice
title_full Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice
title_fullStr Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice
title_full_unstemmed Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice
title_short Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice
title_sort effects of e2hsa a long acting glucagon like peptide 1 receptor agonist on glycemic control and beta cell function in spontaneous diabetic db db mice
url http://dx.doi.org/10.1155/2015/817839
work_keys_str_mv AT shaoconghou effectsofe2hsaalongactingglucagonlikepeptide1receptoragonistonglycemiccontrolandbetacellfunctioninspontaneousdiabeticdbdbmice
AT cainali effectsofe2hsaalongactingglucagonlikepeptide1receptoragonistonglycemiccontrolandbetacellfunctioninspontaneousdiabeticdbdbmice
AT yihuan effectsofe2hsaalongactingglucagonlikepeptide1receptoragonistonglycemiccontrolandbetacellfunctioninspontaneousdiabeticdbdbmice
AT shuainanliu effectsofe2hsaalongactingglucagonlikepeptide1receptoragonistonglycemiccontrolandbetacellfunctioninspontaneousdiabeticdbdbmice
AT quanliu effectsofe2hsaalongactingglucagonlikepeptide1receptoragonistonglycemiccontrolandbetacellfunctioninspontaneousdiabeticdbdbmice
AT sujuansun effectsofe2hsaalongactingglucagonlikepeptide1receptoragonistonglycemiccontrolandbetacellfunctioninspontaneousdiabeticdbdbmice
AT qianjiang effectsofe2hsaalongactingglucagonlikepeptide1receptoragonistonglycemiccontrolandbetacellfunctioninspontaneousdiabeticdbdbmice
AT chunmingjia effectsofe2hsaalongactingglucagonlikepeptide1receptoragonistonglycemiccontrolandbetacellfunctioninspontaneousdiabeticdbdbmice
AT zhufangshen effectsofe2hsaalongactingglucagonlikepeptide1receptoragonistonglycemiccontrolandbetacellfunctioninspontaneousdiabeticdbdbmice